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Abstract
Non-nucleoside reverse transcriptase inhibitor (NNRTI) therapy
failed in 30 patients with the typical human immunodeﬁciency virus
type 1 reverse transcriptase K103N mutation, detected using
standard genotyping. Following discontinuation of NNRTI therapy
for a median of 55.9 weeks and a decrease of K103N mutant spe-
cies to undetectable levels in plasma RNA, minority K103N spe-
cies remained detectable, by allele-speciﬁc PCR, for longer
periods of time and at higher frequency, in peripheral blood
mononuclear cell (PBMC) DNA than in plasma RNA (76.7% and
46.7% of samples with residual K103N species detected at median
frequencies of 18.0% and 3.8%, respectively). Analysis of PBMC
DNA should be considered when searching for residual K103N
mutant species in patients previously exposed to NNRTIs.
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Human immunodeﬁciency virus type 1 (HIV-1) is highly prone
to development of drug resistance during antiretroviral treat-
ment. Monitoring for the presence of drug resistance muta-
tions in the virus genome is recommended in clinical practice,
both before starting therapy and when treatment failure
occurs [1]. Routine genotypic resistance testing is performed
through bulk sequencing of RT-PCR-ampliﬁed HIV-1 RNA
obtained from plasma. Although effective population sequenc-
ing methods have been approved for in vitro diagnostic use, this
technology has inherently limited sensitivity, allowing detection
of the most prevalent virus species but not of minority species
accounting for <25% of the whole population [2].
Changes in antiretroviral therapy alter drug pressure and
consequently the relative proportions of the different viral
quasispecies harbouring resistance mutations. Indeed, speciﬁc
drug-resistant variants may even decrease to undetectable
levels following drug discontinuation. The kinetics of
decrease of a drug resistance mutation is a function of multi-
ple factors, including the mutant virus population size, the
role of the mutation in cross-resistance or hypersusceptibili-
ty to the subsequent regimen, and the impact on virus ﬁtness
[3]. In addition, different mutant species may have different
distributions in plasma RNA and peripheral blood mono-
nuclear cell (PBMC) DNA [4].
Detection of drug-resistant minority species is of clinical
relevance, as these can compromise the efﬁcacy of subse-
quent therapy both in drug-naive and in pretreated patients
[5,6]. In this work, we comparatively evaluated plasma RNA
and PBMC DNA as source material for the detection of
residual HIV-1 species harbouring the reverse transcriptase
K103N mutation typically selected under non-nucleoside
reverse transcriptase inhibitor (NNRTI) therapy.
To develop a K103N allele-speciﬁc (AS) PCR-based assay,
the K103N (AAA to AAC) mutation was introduced into the
HIV-1 reference plasmid pNL4-3, using the Quick Change sys-
tem (Stratagene, La Jolla, CA, USA). Wild-type and K103N-
encoding amplicons obtained via PCR from the wild-type and
mutant plasmids, respectively, were titrated and used to gen-
erate the corresponding standard curves (101–106 copies) as
well as log3 dilution mixtures containing 33–0.1% of K103N
mutant DNA in a total amount of 105 DNA copies. Real-time
ampliﬁcation of wild-type and K103N DNA target sequences
was accomplished in separate 40-cycle reactions using
the invariant sense primer P299 (5¢-CAAGAYTTY
TGGGAAGTTCA-3¢, nucleotides 2802–2821 in HXB2) and
either the wild-type-speciﬁc primer P301 (5¢-ACATCCAGT
AYTGTTACTGATTAT-3¢, nucleotides 2858–2881) or the
K103N-speciﬁc primer P307 (5¢-ACATCCAGTAYTGT
TACTGATTAG-3¢, nucleotides 2858–2881) coupled with the
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Taqman probe P300 (5¢-FAM-GGAATACCACAYCCWG
CAGGGWTA-TAMRA-3¢, nucleotides 2829–2852). Whereas
the last base at the 3¢-terminus of the selective primers was
speciﬁc for one of the two targets, the base at –1 from the 3¢-
terminus was deliberately chosen to introduce a mismatch
between the AS primers and their targets. This approach has
been previously shown to facilitate discrimination between
wild-type and mutant target by AS-PCR [7]. Reconstruction
experiments carried out on an ABI PRISM 7000 instrument
showed that the assay is speciﬁc with an annealing tempera-
ture of 51C; that is, 106 copies of wild-type or K103N mutant
target were not detected by the unmatched primer set.
The proportion of K103N mutant target sequences was
calculated as the ratio between the amount of K103N
sequences detected and the sum of the amounts detected
for wild-type and mutant sequences after interpolation using
the reference curve constructed with the 0.1–33% K103N
mutant DNA mixtures. Accuracy and inter-assay reproducibil-
ity were assessed in ﬁve independent experiments. The
mean ± standard deviation values obtained for mixtures
nominally containing 33%, 10%, 3.3%, 1%, 0.33% and 0.1%
mutant DNA were 32.85% ± 5.21%, 10.32% ± 1.44%, 3.39%
± 0.74%, 0.63% ± 0.19%, 0.16% ± 0.05%, and 0.08% ± 0.05%,
respectively.
To minimize the effect of possible polymorphisms in the
target sequences derived from clinical samples, plasma RNA
or PBMC DNA were ampliﬁed with a low-stringency end-
point nested PCR. Primer P220 (5¢-TTCTGCTATTAAGTCT
TTTGMTGGGTCRTA-3¢, nucleotides 3504–3533) was used
to reverse transcribe HIV-1 RNA extracted from plasma.
The ﬁrst PCR round was directed by primers PRO1 (5¢-AA
AAGGGCTGTTGGAAATGTG-3¢, nucleotides 2018–2038)
and P220. One-ﬁftieth of the reaction mixture was then used
as the template for a second ampliﬁcation, using the sense
primer P299 and the antisense primer P328 (5¢-ACA
TCCAGTAYTGTTACTGATTT-3¢, nucleotides 2859–2881).
Primer P328 matches the consensus HIV-1 sequence, and its
3¢-terminus hybridizes with the last base immediately preced-
ing the AS assay target base. This low-stringency ‘curative’
nested ampliﬁcation generates an amplicon in which any pos-
sible polymorphism originally present in the target region for
the AS primers has been converted to the wild type [8]. The
second-round PCR product is thus delimited by the same
sequences targeted by the AS-PCR primers, except for the
deliberately introduced mismatch just one position following
the mutation site of interest. The ﬁnal product was adjusted
to contain 2 · 104 copies/lL, on the basis of ethidium bro-
mide staining of serial four-fold dilutions, and 5 lL was used
for the AS-PCR. On the basis of the reconstruction experi-
ments, the threshold of sensitivity of the assay was set at
0.1%. However, clinical samples in which K103N was
detected at 0.1–1.0% were retested in a separate run, and
considered to contain K103N at the mean rate of the two
tests only if both yielded >0.1% of mutant DNA. Analysis of
21 HIV-1 RNA and DNA samples obtained from chronically
infected drug-naive subjects did not reveal detectable K103N
levels, conﬁrming the speciﬁcity of the assay with clinical
samples.
From the HIV-1 biobank at the HIV Monitoring Service of
the University of Siena, paired PBMC DNA and plasma RNA
samples were selected from patients interrupting NNRTI
therapy because of failure in the presence of K103N (AAC)
as shown by standard genotyping using plasma RNA. The
paired plasma and PBMC extracts obtained at least 16 weeks
after discontinuation of NNRTI therapy were analysed for
the presence of K103N by AS-PCR if plasma RNA was nega-
tive for K103N by population sequencing and contained at
least 10 000 copies of HIV-1 RNA per mL, ensuring that at
least 4000 target RNA copies were subjected to RT-PCR. In
addition, PBMC HIV-1 DNA was quantitated [9] to conﬁrm
that the relative amount of K103N detected was compatible
with the input DNA. On the basis of these criteria, a total
of 30 paired RNA and DNA samples from distinct subjects
were selected, obtained at a median of 55.9 weeks (inter-
quartile range (IQR) 44.6–89.3 weeks) after cessation of
NNRTI therapy. The median cumulative exposure to NNR-
TIs was 61 weeks (IQR 38–99 weeks).
Plasma RNA analysis allowed detection of minority
K103N species in 14 (46.7%) samples at a median frequency
of 3.8% (IQR 2.0–5.9%) (Table 1). PBMC DNA analysis
allowed detection of minority K103N species in 23 (76.7%)
samples at a median frequency of 18.0% (IQR 5.2–33.0%). Of
the three RNA and ﬁve DNA samples in which K103N was
scored at low level in the ﬁrst run (0.1–1.0%), only one
RNA sample was not conﬁrmed to contain K103N at >0.1%
in the second run. The percentage of K103N detected in
PBMC DNA was compatible with the calculated amount of
input HIV-1 DNA in all samples. When the mutant genotype
was detected in both compartments (n = 12), the proportion
of K103N in PBMC DNA was higher than in paired plasma
RNA (median percentage 30.3 vs. 5.1; p 0.006; Wilcoxon
signed rank test). However, there were two cases where
minority K103N species were detected in plasma RNA (1.7%
and 2.3%) but not in PBMC DNA. The proportion of K103N
in RNA, but not in DNA, was inversely correlated with the
time elapsed since NNRTI discontinuation (Spearman rho
)0.46 and )0.16, p 0.011 and p 0.387, for RNA and DNA,
respectively). By contrast, there was no correlation between
the cumulative time of exposure to NNRTIs and the amount
of residual K103N in RNA and DNA (Spearman rho )0.14
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and )0.18, p 0.469 and p 0.342, respectively). Bulk sequence
analysis of the DNA samples in which K103N was detected
by AS-PCR at a frequency of >25% revealed a mixture of
wild-type and mutant codon 103, as expected.
Highly sensitive point mutation assays are relatively easy
to set up, but require appropriate assessment of accuracy
and precision. As shown in reconstruction experiments,
minority species accounting for as little as 0.1% of the total
population can be reliably quantiﬁed. Owing to the average
yield of RNA extraction and reverse transcription, as well as
the limited amount of sample analysed, the threshold of sen-
sitivity is thus conditioned more by the viral load in the
starting material than by the AS-PCR assay itself. A major
limitation of point mutation assays in the ﬁeld of HIV-1 drug
resistance is the large amount of mutations involved. How-
ever, the kinetics of speciﬁc mutations can be effectively
investigated for research purposes. Detection of selected
minority species can also be relevant in clinical practice.
Speciﬁcally, residual K103N can present a problem for subse-
quent therapy in mothers exposed to single-dose nevirapine
to prevent vertical transmission of HIV-1 infection and in
their infected children [10].
Application of AS-PCR for the detection of K103N after
discontinuation of NNRTI therapy in this pilot study
revealed that the use of PBMC DNA allowed in general,
although not always, more sensitive detection of residual
K103N HIV-1.
This ﬁnding is in line with similar studies based on stan-
dard bulk sequence genotyping showing a slower decay of
virus resistance in PBMCs than in plasma after discontinua-
tion of therapy [4,11]. However, a different situation has
been reported with respect to K103N in mothers exposed
to single-dose nevirapine treatment for prevention of vertical
transmission of HIV-1 infection [12]. The apparently slower
K103N decay in plasma in this case may have derived from
limited archiving of the K103N virus in long-lived cells, owing
to the short period of drug exposure as compared with the
rather prolonged exposure to NNRTIs of our pilot popula-
tion. Our case ﬁle was of limited size, and thus did not allow
ﬁrm conclusions to be drawn concerning this point. In addi-
tion, the design was not suitable for the assessment of per-
sistence of K103N in the absence of therapy, as samples
were deliberately selected in cases where K103N mutants
were no longer detectable by standard sequencing. However,
it can be noted that minority K103N mutants were still
detected in 13 of 14 of DNA samples and six of 14 of RNA
samples obtained 96 weeks (range 72–120 weeks) after dis-
continuation of NNRTI treatment. This observation supports
the view that NNRTI resistance mutations persist in the
absence of therapy [13], and it reinforces the recommendation
TABLE 1. Proportion of K103N
mutants detected using allele-spe-
ciﬁc RT-PCR in plasma RNA and
peripheral blood mononuclear cell
(PBMC) DNA following cessation
of non-nucleoside reverse trans-
criptase inhibitor (NNRTI) treat-
ment in subjects previously found
to harbour K103N mutants using
standard sequencing techniques;
the wild-type K103 virus was iden-
tiﬁed in all samples in which the
K103N mutant was calculated to
represent <0.1%
Blood
sample
code
Viral load
Percentage of
K103N mutants NNRTI therapy
HIV-1
plasma RNA
copies/mL
HIV-1 PBMC
DNA
copies/lg
Plasma
RNA
PBMC
DNA
Weeks since
cessation
Weeks of
cumulative
exposure
35326 10 250 2262 5.1 0.2 30.3 8.6
37816 16 208 1250 0.0 17.6 39.7 38.0
41242 13 210 124 6.2 58.3 45.7 42.9
41354 144 010 1676 <0.1 19.9 89.3 63.6
41883 613 125 3311 <0.1 19.2 43.0 54.9
46051 712 091 341 32.9 47.5 18.0 55.4
49814 21 087 661 <0.1 29.4 105.7 41.0
50217 129 104 1062 <0.1 18.0 54.9 19.6
50225 186 220 859 11.7 43.7 20.0 100.3
52048 14 005 1887 5.8 39.7 29.0 38.3
52902 404 201 457 <0.1 9.8 89.4 102.6
53121 339 205 4497 2.3 <0.1 44.6 57.9
53493 16 521 419 2.7 27.6 95.6 102.9
54805 197 407 80 5.4 46.8 81.9 36.3
56188 132 989 827 2.2 0.3 80.4 68.6
56560 38 540 1117 <0.1 <0.1 47.4 20.0
58112 33 050 2363 <0.1 <0.1 57.0 102.0
58649 25 451 541 <0.1 <0.1 49.0 57.9
65862 20 339 886 <0.1 <0.1 99.4 64.3
65945 89 327 2363 2.1 17.4 19.9 97.9
66755 10 251 967 <0.1 20.0 83.9 28.4
67936 42 962 1614 1.7 <0.1 49.9 52.9
67940 835 278 1479 <0.1 0.7 84.1 121.3
68857 74 217 1103 <0.1 0.2 110.4 70.6
69178 22 795 1479 <0.1 <0.1 48.9 124.6
69808 50 338 3053 <0.1 16.8 48.9 98.9
71279 13 017 2579 5.0 33.0 81.3 67.0
74041 215 214 3895 0.3 12.7 81.9 98.6
74873 81 615 4525 <0.1 1.8 107.0 67.9
74946 74 805 393 0.4 5.2 99.9 13.6
850 Clinical Microbiology and Infection, Volume 16 Number 7, July 2010 CMI
ª2009 The Authors
Journal Compilation ª2009 European Society of Clinical Microbiology and Infectious Diseases, CMI, 16, 848–854
to consider patient treatment history when interpreting cur-
rently used genotypic antiretroviral resistance tests.
Acknowledgements
The pNL4-3 plasmid was obtained through the NIH AIDS
Reagent Program.
Transparency Declaration
This work was supported in part by VI Programma Nazio-
nale di Ricerca AIDS, Italian Ministry of Health
(grant 30G.58). The authors do not have an association that
might pose a conﬂict of interest.
References
1. Hirsch MS, Gu¨nthard HF, Schapiro JM et al. Antiretroviral drug resis-
tance testing in adult HIV-1 infection: 2008 recommendations of an
International AIDS Society-USA panel. Clin Infect Dis 2008; 47: 266–
285.
2. Schuurman R, Demeter L, Reichelderfer P, Tijnagel J, de Groot T,
Boucher C. Worldwide evaluation of DNA sequencing approaches
for identiﬁcation of drug resistance mutations in the human immuno-
deﬁciency virus type 1 reverse transcriptase. J Clin Microbiol 1999; 37:
2291–2296.
3. Quin˜ones-Mateu ME, Arts EJ. Virus ﬁtness: concept, quantiﬁcation, and
application to HIV population dynamics. Curr Top Microbiol Immunol
2006; 299: 83–140.
4. Venturi G, Romano L, Carli T et al. Divergent distribution of HIV-1
drug-resistant variants on and off antiretroviral therapy. Antivir Ther
2002; 7: 245–250.
5. Johnson JA, Li JF, Wei X et al. Minority HIV-1 drug resistance mutations
are present in antiretroviral treatment-naı¨ve populations and associate
with reduced treatment efﬁcacy. PLoS Med 2008; 5: 1112–1122.
6. Louvel S, Battegay M, Vernazza P et al. Detection of drug-resistant
HIV minorities in clinical specimens and therapy failure. HIV Med
2008; 9: 133–141.
7. Paredes R, Marconi VC, Campbell TB, Kuritzkes DR. Systematic eval-
uation of allele-speciﬁc real-time PCR for the detection of minor
HIV-1 variants with pol and env resistance mutations. J Virol Methods
2007; 146: 136–146.
8. Svarovskaia ES, Moser MJ, Bae AS, Prudent JR, Miller MD, Borroto-
Esoda K. MultiCode-RTx real-time PCR system for detection of sub-
populations of K65R human immunodeﬁciency virus type 1 reverse
transcriptase mutant viruses in clinical samples. J Clin Microbiol 2006;
44: 4237–4241.
9. Viard JP, Burgard M, Hubert JB et al. Impact of 5 years of maximally
successful highly active antiretroviral therapy on CD4 cell count and
HIV-1 DNA level. AIDS 2004; 18: 45–49.
10. Martinson NA, Morris L, Gray G et al. Selection and persistence of
viral resistance in HIV-infected children after exposure to single-dose
nevirapine. J Acquir Immune Deﬁc Syndr 2007; 44: 148–153.
11. Boucher S, Recordon-Pinson P, Neau D et al. Clonal analysis of
HIV-1 variants in proviral DNA during treatment interruption in
patients with multiple therapy failures. J Clin Virol 2005; 34: 288–
294.
12. Loubser S, Balfe P, Sherman G, Hammer S, Kuhn L, Morris L. Decay
of K103N mutants in cellular DNA and plasma RNA after single-dose
nevirapine to reduce mother-to-child HIV transmission. AIDS 2006;
20: 995–1002.
13. Joly V, Descamps D, Peytavin G et al. Evolution of human immunode-
ﬁciency virus type 1 (HIV-1) resistance mutations in nonnucleoside
reverse transcriptase inhibitors (NNRTIs) in HIV-1-infected patients
switched to antiretroviral therapy without NNRTIs. Antimicrob Agents
Chemother 2004; 48: 172–175.
Venous thrombosis in immunocompetent
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Abstract
In the present study, we retrospectively studied clinical and labo-
ratory ﬁndings associated with cytomegalovirus (CMV) infection
in immunocompetent patients. We focused on severe CMV infec-
tion. Among 38 patients, ﬁve had a severe form of infection: one
had meningitis, one had symptomatic thrombocytopenia and three
had venous thromboses with pulmonary embolism, a rarely
described complication. CMV-induced thrombosis has been
reported in immunocompromised patients such as transplant
recipients and patients with AIDS. Recent case reports have also
described thrombotic phenomena in immunocompetent patients
with CMV infection. Our study suggests that venous thrombosis
during acute CMV infection is an underestimated complication.
Keywords: Complications, cytomegalovirus infection, immuno-
competent patient, venous thrombosis
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